自己細胞療法の世界市場レポート 2025年

自己細胞療法の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.6％で233億3,000万米ドルに成長します。予測期間の成長は、再生医療の継続的成長、医療専門分野にわたる用途の拡大、細胞培養技術の進歩、投資と研究イニシアチブの増加、規制支援、標準化に起因すると考えられます。予測期間における主な動向としては、自動製造技術の開発、治療戦略におけるバイオマーカーの統合、ポイントオブケア細胞処理の登場、造血幹細胞以外の拡大、業界における共同研究、パートナーシップなどが挙げられます。

慢性疾患の急増が自己細胞療法の拡大に拍車をかけると予想されます。慢性疾患は1年以上続くため、継続的な治療が必要となります。自己細胞療法は、個人の培養・増幅された細胞をドナーに再導入することで、そのような疾患の管理・治療に有望です。国立医学図書館の2023年1月の報告書によると、米国では2050年までに50歳以上で少なくとも1つの慢性疾患を持つ人が1億4,266万人に達すると予測されています。したがって、慢性疾患の有病率の高まりが自己細胞療法市場の成長を後押ししています。

高齢化人口の増加は、今後数年間の自己細胞療法市場の成長を促進すると予想されます。高齢化とは、出生率の低下と平均寿命の延長により、人口内の年齢中央値が上昇することを指します。自己細胞療法は、標的を絞った個別化治療の選択肢を提供することで、この人口動態に恩恵をもたらすことができます。例えば、2024年7月、英国を拠点とする公的統計の作成機関である国家統計局は、2022年には英国で約1,270万人が65歳以上となり、総人口の19％を占めると報告しています。予測によれば、2072年にはこの数字は2,210万人に増加し、人口の27％を占めるようになるといいます。その結果、高齢化人口の増加が自己細胞療法市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の自己細胞療法市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の自己細胞療法市場：成長率分析
• 世界の自己細胞療法市場の実績：規模と成長、2019～2024年
• 世界の自己細胞療法市場の予測：規模と成長、2024～2029年、2034年
• 世界の自己細胞療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の自己細胞療法市場：治療法別、実績と予測、2019～2024年、2024～2029年、2034年
• 自己幹細胞療法
• 自己細胞免疫療法
• 世界の自己細胞療法市場：供給源別、実績と予測、2019～2024年、2024～2029年、2034年
• 骨髄
• 表皮
• 間葉系幹細胞
• 造血幹細胞
• 軟骨細胞
• その他
• 世界の自己細胞療法市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• がん
• 神経変性疾患
• 心血管疾患
• 自己免疫疾患
• 整形外科
• 創傷治癒
• その他
• 世界の自己細胞療法市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院・診療所
• 外来センター
• 学術・研究
• その他
• 世界の自己細胞療法市場：自己幹細胞療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 造血幹細胞移植
• 間葉系幹細胞療法
• 脂肪由来幹細胞療法
• 世界の自己細胞療法市場：自己細胞免疫療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• キメラ抗原受容体（CAR）T細胞療法
• 腫瘍浸潤リンパ球（TIL）療法
• 樹状細胞療法

第7章 地域別・国別分析

• 世界の自己細胞療法市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の自己細胞療法市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 自己細胞療法市場：競合情勢
• 自己細胞療法市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Vericel Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Holostem Terapie Avanzate S.r.l. Overview, Products and Services, Strategy and Financial Analysis
  • Pharmicell Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Opexa Therapeutics Inc.
• Tego Science AB
• Brainstorm Cell Therapeutics Inc.
• Caladrius Biosciences Inc.
• Lineage Cell Therapeutics Inc.
• Castle Creek Biosciences Inc.
• Gilead Sciences Inc.
• Johnson & Johnson
• CORESTEM Inc.
• Dendreon Pharmaceuticals LLC
• Medipost Co. Ltd.
• PharmaJet Inc.
• Bioject Medical Technologies Inc.
• Medical International Technology Inc.
• INJEX Pharma AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 自己細胞療法市場2029年：新たな機会を提供する国
• 自己細胞療法市場2029年：新たな機会を提供するセグメント
• 自己細胞療法市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Autologous cell therapy stands as a method within cell therapy where an individual's cells are gathered, processed, and subsequently reintroduced into their own body to address therapeutic needs. It plays a vital role in regenerative medicine, aiming to repair, replace, or rejuvenate damaged tissues or organs.

Within autologous cell therapy, two primary types are prevalent, autologous stem cell therapy and autologous cellular immunotherapies. Autologous stem cell therapy, a specific facet of this therapy, harnesses stem cells sourced from the patient's own body for therapeutic purposes. These stem cells are derived from various sources such as bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, among others. Their applications span across a wide spectrum of medical areas, including cancer, neurodegenerative disorders, cardiovascular issues, autoimmune conditions, orthopedics, and wound healing. This therapy finds application across multiple sectors including hospitals, clinics, ambulatory centers, academic and research institutions, and other healthcare settings, serving as a versatile approach in addressing various health challenges.

The autologous cell therapy market research report is one of a series of new reports from The Business Research Company that provides autologous cell therapy market statistics, including autologous cell therapy industry global market size, regional shares, competitors with a autologous cell therapy market share, detailed autologous cell therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous cell therapy industry. This autologous cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The autologous cell therapy market size has grown rapidly in recent years. It will grow from$10.28 billion in 2024 to $12.19 billion in 2025 at a compound annual growth rate (CAGR) of 18.6%. The growth in the historic period can be attributed to advancements in regenerative medicine, increased prevalence of chronic diseases, enhanced understanding of cellular biology, patient preference for personalized medicine, clinical success and positive outcomes

The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $23.33 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to continued growth in regenerative medicine, expanding applications across medical specialties, advancements in cell culture techniques, increasing investment and research initiatives, regulatory support, and standardization. Major trends in the forecast period include the development of automated manufacturing technologies, integration of biomarkers in treatment strategies, the emergence of point-of-care cell processing, expansion beyond hematopoietic stem cells, collaborations, and partnerships in the industry.

The burgeoning prevalence of chronic diseases is poised to fuel the expansion of autologous cell therapy. Chronic diseases, persisting for more than a year, necessitate continual medical attention. Autologous cell therapy, leveraging an individual's cultivated and amplified cells reintroduced into the donor, holds promise in managing and treating such conditions. According to the National Library of Medicine's January 2023 report, the US is projected to witness 142.66 million people aged 50 and above with at least one chronic condition by 2050. Hence, the heightened prevalence of chronic diseases propels the growth of the autologous cell therapy market.

The increasing aging population is expected to drive the growth of the autologous cell therapy market in the coming years. An aging population refers to the rise in median age within a population due to declining fertility rates and longer life expectancy. Autologous cell therapies can benefit this demographic by providing targeted and personalized treatment options. For instance, in July 2024, the Office of National Statistics, a UK-based producer of official statistics, reported that in 2022, approximately 12.7 million people in the UK were aged 65 and over, representing 19% of the total population. Projections indicate that by 2072, this figure could rise to 22.1 million, making up 27% of the population. Consequently, the growing aging population is fueling the expansion of the autologous cell therapy market.

Technological advancements emerge as a prominent trend shaping the autologous cell therapy market. Market leaders are automating the process to enhance efficiency and ensure sustainability. Lonza, for instance, unveiled the Cocoon Platform in April 2022, a cutting-edge technology streamlining personalized cell and gene therapy manufacturing. This platform, driven by an automated closed system, minimizes contamination risk, upholds manufacturing sterility, substantially bolsters quality, reduces labor and material expenses, and facilitates the scalable production of autologous T-cell products.

Major players in the autologous cell therapy realm are forging strategic partnerships and collaborations to fortify their market positions. Strategic partnerships, fostering collaborative endeavors between multiple entities, aim to achieve specific business objectives. Notably, in March 2022, Novartis inked an initial agreement with Carisma Therapeutics, aiming to manufacture HER 2 targeted CAR-M cell therapy. The collaboration involves transferring Carisma Therapeutics' manufacturing process to Novartis' Cell Therapy Site in the US, scheduling clinical manufacturing to commence in 2023, focusing on treating solid tumors in initial trials.

In October 2023, Clade Therapeutics, a US-based cell therapy company, successfully acquired Gadeta B.V. for an undisclosed sum. This strategic acquisition significantly enriches Clade's repertoire by incorporating innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies tailored for cancer patients into its existing portfolio. Gadeta B.V., based in the Netherlands, specializes in the development of cell therapies.

Major companies operating in the autologous cell therapy market include Bristol-Myers Squibb Company, Novartis AG, Vericel Corporation, Holostem Terapie Avanzate S.r.l., Pharmicell Co. Ltd., Opexa Therapeutics Inc., Tego Science AB, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Lineage Cell Therapeutics Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc., Johnson & Johnson, CORESTEM Inc., Dendreon Pharmaceuticals LLC, Medipost Co. Ltd., PharmaJet Inc., Bioject Medical Technologies Inc., Medical International Technology Inc., INJEX Pharma AG, Lonza Group Ltd., Corning Incorporated, Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca plc, Moderna Inc., Sinovac Biotech Ltd., Valneva SE, Bavarian Nordic A/S, Dynavax Technologies Corporation

North America was the largest region in the autologous cell therapy market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the autologous cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The autologous cell therapy market includes revenues earned by providing services in relation to cell collection, cell processing, cell expansion, or its modification. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autologous Cell Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autologous cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autologous cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autologous cell therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Autologous Stem Cell Therapy; Autologous Cellular Immunotherapies
• 2) By Source: Bone Marrow; Epidermis; Mesenchymal Stem Cells; Hematopoietic Stem Cells; Chondrocytes; Other Sources
• 3) By Application: Cancer; Neurodegenerative Disorders; Cardiovascular Disorders; Autoimmune Disorders; Orthopedics; Wound Healing; Other Applications
• 4) By End User: Hospitals And Clinics; Ambulatory Centers; Academics And Research; Other End-Users
• Subsegments:
• 1) By Autologous Stem Cell Therapy: Hematopoietic Stem Cell Transplantation; Mesenchymal Stem Cell Therapy; Adipose-Derived Stem Cell Therapy
• 2) By Autologous Cellular Immunotherapies: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Tumor-Infiltrating Lymphocyte (TIL) Therapy; Dendritic Cell Therapy
• Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Vericel Corporation; Holostem Terapie Avanzate S.r.l.; Pharmicell Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autologous Cell Therapy Market Characteristics

3. Autologous Cell Therapy Market Trends And Strategies

4. Autologous Cell Therapy Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Autologous Cell Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autologous Cell Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autologous Cell Therapy Market Growth Rate Analysis
• 5.4. Global Autologous Cell Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autologous Cell Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autologous Cell Therapy Total Addressable Market (TAM)

6. Autologous Cell Therapy Market Segmentation

• 6.1. Global Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Therapy
• Autologous Cellular Immunotherapies
• 6.2. Global Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Hematopoietic Stem Cells
• Chondrocytes
• Other Sources
• 6.3. Global Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Other Applications
• 6.4. Global Autologous Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Ambulatory Centers
• Academics And Research
• Other End-Users
• 6.5. Global Autologous Cell Therapy Market, Sub-Segmentation Of Autologous Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation
• Mesenchymal Stem Cell Therapy
• Adipose-Derived Stem Cell Therapy
• 6.6. Global Autologous Cell Therapy Market, Sub-Segmentation Of Autologous Cellular Immunotherapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Antigen Receptor (CAR) T-Cell Therapy
• Tumor-Infiltrating Lymphocyte (TIL) Therapy
• Dendritic Cell Therapy

7. Autologous Cell Therapy Market Regional And Country Analysis

• 7.1. Global Autologous Cell Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autologous Cell Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autologous Cell Therapy Market

• 8.1. Asia-Pacific Autologous Cell Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autologous Cell Therapy Market

• 9.1. China Autologous Cell Therapy Market Overview
• 9.2. China Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autologous Cell Therapy Market

• 10.1. India Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autologous Cell Therapy Market

• 11.1. Japan Autologous Cell Therapy Market Overview
• 11.2. Japan Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autologous Cell Therapy Market

• 12.1. Australia Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autologous Cell Therapy Market

• 13.1. Indonesia Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autologous Cell Therapy Market

• 14.1. South Korea Autologous Cell Therapy Market Overview
• 14.2. South Korea Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autologous Cell Therapy Market

• 15.1. Western Europe Autologous Cell Therapy Market Overview
• 15.2. Western Europe Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autologous Cell Therapy Market

• 16.1. UK Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autologous Cell Therapy Market

• 17.1. Germany Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autologous Cell Therapy Market

• 18.1. France Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autologous Cell Therapy Market

• 19.1. Italy Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autologous Cell Therapy Market

• 20.1. Spain Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autologous Cell Therapy Market

• 21.1. Eastern Europe Autologous Cell Therapy Market Overview
• 21.2. Eastern Europe Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autologous Cell Therapy Market

• 22.1. Russia Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autologous Cell Therapy Market

• 23.1. North America Autologous Cell Therapy Market Overview
• 23.2. North America Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autologous Cell Therapy Market

• 24.1. USA Autologous Cell Therapy Market Overview
• 24.2. USA Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autologous Cell Therapy Market

• 25.1. Canada Autologous Cell Therapy Market Overview
• 25.2. Canada Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autologous Cell Therapy Market

• 26.1. South America Autologous Cell Therapy Market Overview
• 26.2. South America Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autologous Cell Therapy Market

• 27.1. Brazil Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autologous Cell Therapy Market

• 28.1. Middle East Autologous Cell Therapy Market Overview
• 28.2. Middle East Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autologous Cell Therapy Market

• 29.1. Africa Autologous Cell Therapy Market Overview
• 29.2. Africa Autologous Cell Therapy Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autologous Cell Therapy Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autologous Cell Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autologous Cell Therapy Market Competitive Landscape And Company Profiles

• 30.1. Autologous Cell Therapy Market Competitive Landscape
• 30.2. Autologous Cell Therapy Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Vericel Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Holostem Terapie Avanzate S.r.l. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pharmicell Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Autologous Cell Therapy Market Other Major And Innovative Companies

• 31.1. Opexa Therapeutics Inc.
• 31.2. Tego Science AB
• 31.3. Brainstorm Cell Therapeutics Inc.
• 31.4. Caladrius Biosciences Inc.
• 31.5. Lineage Cell Therapeutics Inc.
• 31.6. Castle Creek Biosciences Inc.
• 31.7. Gilead Sciences Inc.
• 31.8. Johnson & Johnson
• 31.9. CORESTEM Inc.
• 31.10. Dendreon Pharmaceuticals LLC
• 31.11. Medipost Co. Ltd.
• 31.12. PharmaJet Inc.
• 31.13. Bioject Medical Technologies Inc.
• 31.14. Medical International Technology Inc.
• 31.15. INJEX Pharma AG

32. Global Autologous Cell Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autologous Cell Therapy Market

34. Recent Developments In The Autologous Cell Therapy Market

35. Autologous Cell Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Autologous Cell Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autologous Cell Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autologous Cell Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer